InVitria launches Optibumin® 25, the first recombinant 25% rHSA for closed-system use, enabling safer, scalable ...

Optibumin® 25 – a 25% recombinant human serum albumin (rHSA) solution developed ... For decades, plasma-derived HSA has presented regulatory and supply chain challenges, including batch ...

A Wuhan-based biopharmaceutical company developed technology to synthesize human serum albumin (HSA) from rice, offering a potential solution to China's supply shortage of this critical blood protein.

InVitria, a leading developer of recombinant, chemically defined components for biomanufacturing, has announced the launch of Optibumin® 25, the first and only recombinant human serum albumin ...

Optibumin® 25 is the first recombinant 25% human serum albumin for closed-system biomanufacturing, offering consistency, sterility, and GMP compliance. For decades, plasma-derived HSA has ...

Medical scientists said the breakthrough will help alleviate China's shortage of human serum albumin (HSA). HSA is a blood product vital in the treatment of a number of medical conditions ...

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced ...